Minimal Residual Diseases (MRD): Hematology Journal Club 2

Speaker
Multiple
Category:
Leukemia

This journal club was a scientific-educational activity discussing data from BLAST trial, reflecting on the role of achieving and sustaining Minimal Residual Disease negativity status. The Role of Blinatumomab in managing Minimal Residual Disease (MRD) in B-Cell Acute Lymphoblastic Leukemia (B-ALL).
One of its key goals was to share clinical experience on the use of Blinatumomab in MRD+ adult ALL patients.

1
Confirmatory Phase II of Blinatumomab(MT103) In Patients with Minimal Residual Disease of B-Precursor ALL
120 minutes

Speaker: Sabir Hussain

Affiliations: Consultant Hematologist & Oncologists, Tawam Hospital, Al Ain, United Arab Emirates

 

This presentation was part of a scientific educational activity discussing data from BLAST trial, reflecting on the role of achieving and sustaining Minimal Residual Disease negativity status . The Role of Blinatumomab in managing Minimal Residual Disease (MRD) in B-Cell Acute Lymphoblastic Leukemia (B-ALL).

2
Case Presentation ( MRD+ Case) From Mediclinic Hospital
10 minutes

Speaker: Mahmoud Marashi 

Affiliations: Consultant Hematologist, Mediclinic City Hospital, , United Arab Emirates

 

This presentation was part of a scientific educational activity discussing data from BLAST trial, reflecting on the role of achieving and sustaining Minimal Residual Disease negativity status . The Role of Blinatumomab in managing Minimal Residual Disease (MRD) in B-Cell Acute Lymphoblastic Leukemia (B-ALL).

3
Cytokine Release Syndrome in Patients Receiving Therapy for Acute Lymphoblastic Leukemia
35 minutes

Speaker: Hani Osman

Affiliations: Consultant Hematologist, Tawam Hospital, United Arab Emirates

 

 

This presentation was part of a scientific educational activity discussing data from BLAST trial, reflecting on the role of achieving and sustaining Minimal Residual Disease negativity status. The Role of Blinatumomab in managing Minimal Residual Disease (MRD) in B-Cell Acute Lymphoblastic Leukemia (B-ALL).

4
Hematology Journal Club 2.0: Panel Discussion
17 minutes

Panel Discussion including Mahmoud Marashi and Hani Osman. 

5
Test your knowledge related to malignant
15 questions
Add to Wishlist
Enroll course
Enrolled: 7 students
Presentations: 4
eaccme

Accreditation Statement

The Hematology Live Online Education, made available on https://hematologylive.online/ and organized by Meeting Minds Experts, is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.

 

Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Only those e-learning materials that are displayed on the UEMSEACCME website have formally been accredited.

 

Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.